353 related articles for article (PubMed ID: 31792895)
1. Modeling Polyglutamine Expansion Diseases with Induced Pluripotent Stem Cells.
Naphade S; Tshilenge KT; Ellerby LM
Neurotherapeutics; 2019 Oct; 16(4):979-998. PubMed ID: 31792895
[TBL] [Abstract][Full Text] [Related]
2. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes.
HD iPSC Consortium
Cell Stem Cell; 2012 Aug; 11(2):264-78. PubMed ID: 22748968
[TBL] [Abstract][Full Text] [Related]
3. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders.
Sánchez I; Mahlke C; Yuan J
Nature; 2003 Jan; 421(6921):373-9. PubMed ID: 12540902
[TBL] [Abstract][Full Text] [Related]
4. Polyalanine and polyserine frameshift products in Huntington's disease.
Davies JE; Rubinsztein DC
J Med Genet; 2006 Nov; 43(11):893-6. PubMed ID: 16801344
[TBL] [Abstract][Full Text] [Related]
5. Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons.
Tydlacka S; Wang CE; Wang X; Li S; Li XJ
J Neurosci; 2008 Dec; 28(49):13285-95. PubMed ID: 19052220
[TBL] [Abstract][Full Text] [Related]
6. DNAJB6, a Key Factor in Neuronal Sensitivity to Amyloidogenesis.
Thiruvalluvan A; de Mattos EP; Brunsting JF; Bakels R; Serlidaki D; Barazzuol L; Conforti P; Fatima A; Koyuncu S; Cattaneo E; Vilchez D; Bergink S; Boddeke EHWG; Copray S; Kampinga HH
Mol Cell; 2020 Apr; 78(2):346-358.e9. PubMed ID: 32268123
[TBL] [Abstract][Full Text] [Related]
7. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders.
Ross CA
Neuron; 2002 Aug; 35(5):819-22. PubMed ID: 12372277
[TBL] [Abstract][Full Text] [Related]
8. The pathogenic agent in Drosophila models of 'polyglutamine' diseases.
McLeod CJ; O'Keefe LV; Richards RI
Hum Mol Genet; 2005 Apr; 14(8):1041-8. PubMed ID: 15757976
[TBL] [Abstract][Full Text] [Related]
9. [Polyglutamine diseases: a pathologic view].
Yamada M
Rinsho Shinkeigaku; 2003 Nov; 43(11):903-5. PubMed ID: 15152499
[TBL] [Abstract][Full Text] [Related]
10. Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease?
Kennedy L; Shelbourne PF
Hum Mol Genet; 2000 Oct; 9(17):2539-44. PubMed ID: 11030759
[TBL] [Abstract][Full Text] [Related]
11. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
12. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
Wyttenbach A; Swartz J; Kita H; Thykjaer T; Carmichael J; Bradley J; Brown R; Maxwell M; Schapira A; Orntoft TF; Kato K; Rubinsztein DC
Hum Mol Genet; 2001 Aug; 10(17):1829-45. PubMed ID: 11532992
[TBL] [Abstract][Full Text] [Related]
13. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells.
An MC; Zhang N; Scott G; Montoro D; Wittkop T; Mooney S; Melov S; Ellerby LM
Cell Stem Cell; 2012 Aug; 11(2):253-63. PubMed ID: 22748967
[TBL] [Abstract][Full Text] [Related]
14. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.
Hannan AJ
Acta Biochim Pol; 2004; 51(2):415-30. PubMed ID: 15218539
[TBL] [Abstract][Full Text] [Related]
15. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.
Juopperi TA; Kim WR; Chiang CH; Yu H; Margolis RL; Ross CA; Ming GL; Song H
Mol Brain; 2012 May; 5():17. PubMed ID: 22613578
[TBL] [Abstract][Full Text] [Related]
16. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
Bogomazova AN; Eremeev AV; Pozmogova GE; Lagarkova MA
Mol Biol (Mosk); 2019; 53(6):954-967. PubMed ID: 31876275
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.
Reis SD; Pinho BR; Oliveira JMA
Mol Neurobiol; 2017 Oct; 54(8):5829-5854. PubMed ID: 27660272
[TBL] [Abstract][Full Text] [Related]
18. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?
Davies SW; Beardsall K; Turmaine M; DiFiglia M; Aronin N; Bates GP
Lancet; 1998 Jan; 351(9096):131-3. PubMed ID: 9439509
[TBL] [Abstract][Full Text] [Related]
19. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient.
Chae JI; Kim DW; Lee N; Jeon YJ; Jeon I; Kwon J; Kim J; Soh Y; Lee DS; Seo KS; Choi NJ; Park BC; Kang SH; Ryu J; Oh SH; Shin DA; Lee DR; Do JT; Park IH; Daley GQ; Song J
Biochem J; 2012 Sep; 446(3):359-71. PubMed ID: 22694310
[TBL] [Abstract][Full Text] [Related]
20. Towards a transgenic model of Huntington's disease in a non-human primate.
Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
